Real-life data of luspatercept in lower-risk myelodysplastic syndromes advocate new research objectives
EJHaem
.
2024 Oct 4;5(5):1096-1099.
doi: 10.1002/jha2.1027.
eCollection 2024 Oct.
Authors
Bert Heyrman
1
,
Stef Meers
2
,
Sélim Sid
3
,
Natalie Put
4
,
Koen Theunissen
5
,
Koen Van Eygen
6
,
Nathan De Beule
7
,
Maxime Clauwaert
8
,
Helena Maes
9
,
Alexander Salembier
10
,
Jan Lemmens
11
,
Ann Van De Velde
12
,
Dominik Selleslag
13
,
Jason Bouziotis
14
,
Ann De Becker
7
,
Sébastien Anguille
12
Affiliations
1
Department of Haematology Ziekenhuis Netwerk Antwerpen Antwerp Belgium.
2
Department of Haematology Algemeen Ziekenhuis Klina Brasschaat Belgium.
3
Department of Haematology Centre Hospitalier Régional Verviers Verviers Belgium.
4
Department of Haematology Ziekenhuis Oost-Limburg Genk Belgium.
5
Department of Haematology Jessa Ziekenhuis Hasselt Belgium.
6
Department of Haematology Algemeen Ziekenhuis Groeninge Kortrijk Belgium.
7
Department of Haematology Universitair Ziekenhuis Brussel Jette Belgium.
8
Department of Haematology Algemeen Ziekenhuis Sint-Lucas Gent Belgium.
9
Department of Haematology Imelda Ziekenhuis Bonheiden Belgium.
10
Department of Haematology Algemeen Ziekenhuis Glorieux Ronse Belgium.
11
Department of Haematology Gasthuiszusters Antwerpen Antwerp Belgium.
12
Department of Haematology Universitair Ziekenhuis Antwerpen Edegem Belgium.
13
Department of Haematology Algemeen Ziekenhuis Sint-Jan Bruges Belgium.
14
Clinical Trial Center Universitair Ziekenhuis Antwerpen Edegem Belgium.
PMID:
39415916
PMCID:
PMC11474394
DOI:
10.1002/jha2.1027
No abstract available